Literature DB >> 6106099

Response to pneumococcal polysaccharide vaccine in patients with untreated Hodgkin's disease. Children's Cancer Study Group Report.

J E Addiego, A J Ammann, G Schiffman, R Baehner, G Higgins, D Hammond.   

Abstract

Patients with Hodgkin's disease (HD) have a high risk of overwhelming pneumococcal infections after splenectomy. Previous studies have shown that HD patients given polyvalent pneumococcal polysaccharide (PPS) vaccine after immunosuppressive therapy have a suboptimum antibody response. This study shows significant antibody response in HD patients to PPS vaccine given before radiation and chemotherapy. The same response was obtained whether the vaccine was given before or after splenectomy.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6106099     DOI： 10.1016/s0140-6736(80)91887-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  9 in total

Review 1.  Periodic health examination, 1991 update: 2. Administration of pneumococcal vaccine. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1991-03-15       Impact factor: 8.262

Review 2.  Pneumococcal vaccine.

Authors:  R T White
Journal:  Thorax       Date:  1988-05       Impact factor: 9.139

3.  Increased risk of sepsis after splenectomy.

Authors:  H A Deodhar; R J Marshall; J N Barnes
Journal:  BMJ       Date:  1993-11-27

4.  Chemotherapy and irradiation in childhood Hodgkin's disease.

Authors:  B Robinson; J Kingston; R Nogueira Costa; J S Malpas; A Barrett; T J McElwain
Journal:  Arch Dis Child       Date:  1984-12       Impact factor: 3.791

5.  Antibody responses of splenectomized patients with non-Hodgkin's lymphoma to immunization with polyvalent pneumococcal vaccines.

Authors:  S Petrasch; O Kühnemund; A Reinacher; M Uppenkamp; R Reinert; W Schmiegel; R Lütticken; G Brittinger
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

Review 6.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

7.  Effect of 23-Valent Pneumococcal Polysaccharide Vaccine Inoculated During Anti-Cancer Treatment Period in Elderly Lung Cancer Patients on Community-Acquired Pneumonia Hospitalization: A Nationwide Population-Based Cohort Study.

Authors:  Wen-Yen Chiou; Shih-Kai Hung; Chun-Liang Lai; Hon-Yi Lin; Yu-Chieh Su; Yi-Chun Chen; Bing-Jie Shen; Liang-Cheng Chen; Shiang-Jiun Tsai; Moon-Sing Lee; Chung-Yi Li
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

8.  Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial.

Authors:  Wonyoung Choi; Jong Gwang Kim; Seung-Hoon Beom; Jun-Eul Hwang; Hyun-Jung Shim; Sang-Hee Cho; Min-Ho Shin; Sin-Ho Jung; Ik-Joo Chung; Joon Young Song; Woo Kyun Bae
Journal:  Cancer Res Treat       Date:  2019-07-09       Impact factor: 4.679

9.  Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study.

Authors:  Wen-Yen Chiou; Moon-Sing Lee; Shih-Kai Hung; Hon-Yi Lin; Yuan-Chen Lo; Feng-Chun Hsu; Shiang-Jiun Tsai; Chung-Yi Li
Journal:  BMJ Open       Date:  2018-05-16       Impact factor: 2.692
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.